EUCTR2018-001070-20-ES进行中（未招募）1 期
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination with Various Standard-of-Care Therapeutic Regimens, in Participants with Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically or cytologically confirmed locally advanced or recurrent or metastatic GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery
- •- Evidence of progressive disease (PD) on at least one prior platinum and fluoropyrimidine-containing chemotherapy regimen
- •- Available tumor tissue for biomarker analysis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1526
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 654
排除标准
- •- Squamous cell or undifferentiated GC or GEJ
- •- Untreated known central nervous system (CNS) metastases
- •- Prior treatment with relatlimab or any other LAG-3 targeted agents
研究者
相似试验
已完成
1 期
Phase I Clinical Trial of SII Yellow Fever VaccineCTRI/2020/09/027594Serum Institute of India Pvt Ltd60
已完成
1 期
A clinical study to assess the safety and immune response of rabies vaccine of Serum Institute of India Ltd (SIIL).CTRI/2011/07/001903Serum Institute of India Ltd60
已完成
2 期
A study of Purified Vero Rabies vaccine for prophylaxis in patients with rabies exposureCTRI/2012/11/003135Serum Institute of India Limited181
招募中
1 期
Setrusumab vs Bisphosphonates in Pediatric Subjects with Osteogenesis ImperfectaMedDRA version: 20.0Level: PTClassification code: 10031243Term: Osteogenesis imperfecta Class: 100000004850osteogenesis imperfectaCTIS2023-504196-24-00ltragenyx Pharmaceutical Inc.68
尚未招募
2 期
Effect of Herbal medicine, Allopathic medicine and lifestyle modification on newly diagnosed diabetes.CTRI/2023/09/057282Maharashtra University of health sciences Nashik